KU14R
(Synonyms:2-(2-乙基-2,3-二氢-2-苯并呋喃基)-1H-咪唑)
目录号 : KG10813
CAS No. : 189224-48-4
纯度 : 98%
KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.IC50 Value:Target: Insulin ReceptorA new I(3)-R antagonist, KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl)-2-imidazole), which selectively blocks the insulin secretory response to imidazolines. KU14R partially attenuated responses to Imidazole-4-acetic acid-ribotide (IAA-RP). The effects of KU14R on stimulus secretion-coupling in normal mouse islets and beta cells was compared by measuring KATP channel activity, plasma membrane potential, cytosolic calcium concentration ([Ca2+]c) and dynamic insulin secretion. In the presence of 10 mmol/l but not of 5 mmol/l glucose, KU14R (30, 100 or 300 micromol/l) was ineffective. KATP channel was blocked by KU14R (IC50 31.9 micromol/l, Hill slope -1.5). KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo.
Other Forms of Rapamycin:
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
KKL 顾客使用本产品发表的 0 篇科研文献
暂无科研文献
分子式 |
C13H14N2O
|
分子量 |
214.26
|
CAS号 |
189224-48-4
|
中文名称 |
KU14R
|
储存方式 |
Store at -20°C
|